A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib (INCB039110) in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Trial Profile

A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Itacitinib (INCB039110) in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 25 Jun 2017

At a glance

  • Drugs INCB 50465 (Primary) ; Itacitinib (Primary) ; Carboplatin; Etoposide; Ifosfamide; Rituximab
  • Indications B cell lymphoma; Hodgkin's disease
  • Focus Adverse reactions
  • Acronyms CITADEL-101
  • Sponsors Incyte Corporation
  • Most Recent Events

    • 25 Jun 2017 Results (n = 52) presented at the 22nd Congress of the European Haematology Association.
    • 06 Jun 2017 Initial safety and efficacy results (n=52) as of data cut-off dated Nov 1, 2016, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 16 May 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top